These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Aspartylglucosaminidase (AGA) is efficiently produced and endocytosed by glial cells: implication for the therapy of a lysosomal storage disorder. Harkke S, Laine M, Jalanko A. J Gene Med; 2003 Jun; 5(6):472-82. PubMed ID: 12797112 [Abstract] [Full Text] [Related]
6. Overgrowth of oral mucosa and facial skin, a novel feature of aspartylglucosaminuria. Arvio P, Arvio M, Kero M, Pirinen S, Lukinmaa PL. J Med Genet; 1999 May; 36(5):398-404. PubMed ID: 10353787 [Abstract] [Full Text] [Related]
8. Correction of deficient enzyme activity in a lysosomal storage disease, aspartylglucosaminuria, by enzyme replacement and retroviral gene transfer. Enomaa N, Danos O, Peltonen L, Jalanko A. Hum Gene Ther; 1995 Jun; 6(6):723-31. PubMed ID: 7548272 [Abstract] [Full Text] [Related]
13. Identification of a novel mutation causing aspartylglucosaminuria reveals a mutation hotspot region in the aspartylglucosaminidase gene. Isoniemi A, Hietala M, Aula P, Jalanko A, Peltonen L. Hum Mutat; 1995 Jun; 5(4):318-26. PubMed ID: 7627186 [Abstract] [Full Text] [Related]